评估对 SARS-CoV2 疫苗免疫反应的持续时间:疫苗接种后尖峰蛋白抗体效价队列回顾

Zein Kattih , Jonathan Moore , Dimitre G. Stefanov , Priyanka Makkar , Viera Lakticova
{"title":"评估对 SARS-CoV2 疫苗免疫反应的持续时间:疫苗接种后尖峰蛋白抗体效价队列回顾","authors":"Zein Kattih ,&nbsp;Jonathan Moore ,&nbsp;Dimitre G. Stefanov ,&nbsp;Priyanka Makkar ,&nbsp;Viera Lakticova","doi":"10.1016/j.clicom.2024.01.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The SARS-CoV2 pandemic required rapid development and expedited evaluation of vaccine efficacy. Initial evidence suggested waning immune response to SARS-CoV2 vaccination steadily over the first six months. This study evaluated duration of immunity in vaccinated patients at a single tertiary center in New York City during the pandemic.</p></div><div><h3>Methods</h3><p>We conducted a retrospective review of adult vaccinated patients admitted over a period of 3 months during the SARS-CoV2-Omicron variant and evaluated their immune response using the spike protein antibody titer. A total of 2476 patients were screened, and 1875 patients were included in the study. Secondary analysis of a cohort of patients with COVID-19 disease was also performed.</p></div><div><h3>Results</h3><p>Spike protein antibody was positive in 99 % of patients. Most patients received two doses of the Pfizer (42 %) or the Moderna (27 %) vaccines. There was a negative correlation between months since vaccination and spike protein antibody titer (Spearman's rank correlation –0.094, <em>p</em> &lt;0.0001). Subgroup analysis of those who had received at least two doses of a vaccine series revealed similar negative correlations for both Pfizer (Spearman's rank correlation –0.14, <em>p</em> &lt;0.0001) and Moderna vaccines (Spearman's rank correlation –0.11, <em>p</em> = 0.0043). Secondary analysis of patients admitted with a diagnosis of COVID-19 infection did not demonstrate any statistically significant difference in titer results over time.</p></div><div><h3>Conclusions</h3><p>Our study of patients admitted to a tertiary care center across a diverse patient population demonstrated that patients who were vaccinated against SARS-COV2 had a robust response in their spike protein antibody titer which was maintained well beyond six months after vaccination.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613424000015/pdfft?md5=f4633bf721f316ced2394d5c29235569&pid=1-s2.0-S2772613424000015-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Evaluating length of immune response to SARS-CoV2 vaccine: A cohort review of spike protein antibody titer after vaccination\",\"authors\":\"Zein Kattih ,&nbsp;Jonathan Moore ,&nbsp;Dimitre G. Stefanov ,&nbsp;Priyanka Makkar ,&nbsp;Viera Lakticova\",\"doi\":\"10.1016/j.clicom.2024.01.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>The SARS-CoV2 pandemic required rapid development and expedited evaluation of vaccine efficacy. Initial evidence suggested waning immune response to SARS-CoV2 vaccination steadily over the first six months. This study evaluated duration of immunity in vaccinated patients at a single tertiary center in New York City during the pandemic.</p></div><div><h3>Methods</h3><p>We conducted a retrospective review of adult vaccinated patients admitted over a period of 3 months during the SARS-CoV2-Omicron variant and evaluated their immune response using the spike protein antibody titer. A total of 2476 patients were screened, and 1875 patients were included in the study. Secondary analysis of a cohort of patients with COVID-19 disease was also performed.</p></div><div><h3>Results</h3><p>Spike protein antibody was positive in 99 % of patients. Most patients received two doses of the Pfizer (42 %) or the Moderna (27 %) vaccines. There was a negative correlation between months since vaccination and spike protein antibody titer (Spearman's rank correlation –0.094, <em>p</em> &lt;0.0001). Subgroup analysis of those who had received at least two doses of a vaccine series revealed similar negative correlations for both Pfizer (Spearman's rank correlation –0.14, <em>p</em> &lt;0.0001) and Moderna vaccines (Spearman's rank correlation –0.11, <em>p</em> = 0.0043). Secondary analysis of patients admitted with a diagnosis of COVID-19 infection did not demonstrate any statistically significant difference in titer results over time.</p></div><div><h3>Conclusions</h3><p>Our study of patients admitted to a tertiary care center across a diverse patient population demonstrated that patients who were vaccinated against SARS-COV2 had a robust response in their spike protein antibody titer which was maintained well beyond six months after vaccination.</p></div>\",\"PeriodicalId\":100269,\"journal\":{\"name\":\"Clinical Immunology Communications\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2772613424000015/pdfft?md5=f4633bf721f316ced2394d5c29235569&pid=1-s2.0-S2772613424000015-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Immunology Communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2772613424000015\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Immunology Communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772613424000015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景SARS-CoV2 大流行要求快速开发疫苗并加快对疫苗功效的评估。初步证据表明,在最初的六个月中,接种 SARS-CoV2 疫苗后的免疫反应会逐渐减弱。我们对 SARS-CoV2-Omicron 变异期间 3 个月内收治的成年疫苗接种患者进行了回顾性审查,并使用尖峰蛋白抗体滴度评估了他们的免疫反应。共有 2476 名患者接受了筛查,其中 1875 名患者被纳入研究。结果99%的患者尖峰蛋白抗体呈阳性。大多数患者接种了两剂辉瑞疫苗(42%)或莫德纳疫苗(27%)。接种疫苗后的月数与尖峰蛋白抗体滴度呈负相关(Spearman's rank correlation -0.094, p <0.0001)。对至少接种过两剂疫苗的患者进行分组分析后发现,辉瑞疫苗(Spearman秩相关-0.14,p <0.0001)和Moderna疫苗(Spearman秩相关-0.11,p = 0.0043)也存在类似的负相关。对诊断为 COVID-19 感染的入院患者进行的二次分析表明,随着时间的推移,滴度结果没有任何统计学意义上的显著差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Evaluating length of immune response to SARS-CoV2 vaccine: A cohort review of spike protein antibody titer after vaccination

Background

The SARS-CoV2 pandemic required rapid development and expedited evaluation of vaccine efficacy. Initial evidence suggested waning immune response to SARS-CoV2 vaccination steadily over the first six months. This study evaluated duration of immunity in vaccinated patients at a single tertiary center in New York City during the pandemic.

Methods

We conducted a retrospective review of adult vaccinated patients admitted over a period of 3 months during the SARS-CoV2-Omicron variant and evaluated their immune response using the spike protein antibody titer. A total of 2476 patients were screened, and 1875 patients were included in the study. Secondary analysis of a cohort of patients with COVID-19 disease was also performed.

Results

Spike protein antibody was positive in 99 % of patients. Most patients received two doses of the Pfizer (42 %) or the Moderna (27 %) vaccines. There was a negative correlation between months since vaccination and spike protein antibody titer (Spearman's rank correlation –0.094, p <0.0001). Subgroup analysis of those who had received at least two doses of a vaccine series revealed similar negative correlations for both Pfizer (Spearman's rank correlation –0.14, p <0.0001) and Moderna vaccines (Spearman's rank correlation –0.11, p = 0.0043). Secondary analysis of patients admitted with a diagnosis of COVID-19 infection did not demonstrate any statistically significant difference in titer results over time.

Conclusions

Our study of patients admitted to a tertiary care center across a diverse patient population demonstrated that patients who were vaccinated against SARS-COV2 had a robust response in their spike protein antibody titer which was maintained well beyond six months after vaccination.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信